The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials

Table 1

Study characteristics and baseline demographic characteristics in meta-analysis.

Study, year published	Intervention	No. of patients	Study duration	Therapy duration	Study population	Study design	Study site	Female (%)	Mean ± S.D. age (years)
Smith et al. [16], 2017	Teprotumumab	43	July 2013 and September 2015	24 weeks	18–75 years	Phase 2	15 sites in the United States and Europe	28 (65)	51.6 ± 10.6
	Placebo	44						36 (82)	54.2 ± 13.0
Douglas et al. [18], 2020	Teprotumumab	41	October 2017 and August 2018	24 weeks	18–80 years	Phase 3	13 sites in the United States and Europe	29 (71)	51.6 ± 12.6
	Placebo	42						31 (74)	48.9 ± 13.0
Kahaly et al. [17], 2021	Teprotumumab	84	October 2017 and August 2018	24 weeks	18–75 years	Phase 3	28 sites in Europe and the USA	58 (69)	51·5 ± 11·6
	Placebo	87						67 (77)	51·4 ± 13·1